Following a lackluster 2024, shares of major drugmakers kicked off 2025 with an upbeat quarterly results reading. U.S. pharmaceuticals like Eli Lilly (LLY), Johnson & Johnson (JNJ), Bristol-Myers ...

The world’s population is aging at an unprecedented pace. According to WHO’s October 2024 report, the number of people aged 60 and older surpassed children under five for the first time in 2020. By ...

The wealth of Dr. Mehmet Oz, the celebrity heart surgeon nominated by President Donald Trump to lead the Centers for Medicare and Medicaid Services, has swelled in part from ...

Mehmet Oz, Trump's nominee to lead the Centers for Medicare and Medicaid Services, pledged to divest his investments in hospitals and insurers if confirmed to lead the agency, he said in a filing with ...

Our health care system is in critical condition, and it’s core sickness is monopolies,” she said in a virtual event ...

Colossal Biosciences cofounder and CEO Ben Lamm is worth $3.7 billion following the company's recent fundraise at an ...

From the ashes of the past there grow the fires of the future.” So begins 1975’s Giant-Size X-Men #1, written by Len Wein and ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...